ArticleCancer immunology, immunotherapy : CII2015
Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.
Article in Cancer immunology, immunotherapy : CII, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Vaccination against tumour endothelial marker Robo4 inhibits tumour growth.Immunotherapy advances · 2026Article
- Review
- DNA vaccines as promising immuno-therapeutics against cancer: a new insight.Frontiers in immunology · 2024Review
- Advances and challenges in anti-cancer vaccines for multiple myeloma.Frontiers in immunology · 2024Review
- Immunotherapy approaches for hematological cancers.iScience · 2022Review
- Article
- Tetanus Toxin Fragment C: Structure, Drug Discovery Research and Production.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Cancer vaccines as promising immuno-therapeutics: platforms and current progress.Journal of hematology & oncology · 2022Review
- Immunotherapy for the treatment of multiple myeloma.Frontiers in immunology · 2022Review
- scFv6.C4 DNA vaccine with fragment C of tetanus toxin increases protective immunity against CEA-expressing tumor.Gene therapy · 2021Article
- Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities.Frontiers in oncology · 2020Review
- scFv6.C4 DNA vaccine with fragment C of Tetanus toxin increases protective immunity against CEA-expressing tumor.Gene therapy · 2019Article
- Cancer DNA vaccines: current preclinical and clinical developments and future perspectives.Journal of experimental & clinical cancer research : CR · 2019Review
- Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?Current hematologic malignancy reports · 2019Review
- Is immunotherapy here to stay in multiple myeloma?Haematologica · 2017Review
- A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer.Oncoimmunology · 2016Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
We report on the safety and immunogenicity of idiotypic DNA vaccination in a phase I, non-randomised, open-label study in patients with multiple myeloma. The study used DNA fusion gene vaccines encoding patient-specific single chain variable fragment, or idiotype (Id), linked to fragment C (FrC) of tetanus toxin. Patients in complete or partial response following high-dose chemotherapy and autologous stem cell transplant were vaccinated intramuscularly with 1 mg DNA on six occasions, beginning at least 6 months post-transplant; follow-up was to week 52. Fourteen patients were enrolled on study and completed vaccinations. Idiotypic DNA vaccines were well tolerated with vaccine-related adverse events limited to low-grade constitutional symptoms. FrC- and Id-specific T-cell responses were detected by ex vivo ELISPOT in 9/14 and 3/14 patients, respectively. A boost of pre-existing anti-FrC antibody (Ab) was detected by ELISA in 8/14 patients, whilst anti-Id Ab was generated in 1/13 patients. Overall, four patients (29 %) made an immune response to FrC and Id, with six patients (43 %) responding to FrC alone. Over the 52-week study period, serum paraprotein was undetectable, decreased or remained stable for ten patients (71 %), whilst ongoing CR/PR was maintained for 11 patients (79 %). The median time to progression was 38.0 months for 13/14 patients. Overall survival was 64 % after a median follow-up of 85.6 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.